PD-1 Inhibition and the Changing Frontline Landscape of Advanced Classical Hodgkin Lymphoma: A Narrative Review with a Focus on Applicability in Lower- and Middle-Income Settings
Frontline management of advanced-stage classical Hodgkin lymphoma (cHL) has been transformed by PET adapted therapy, brentuximab vedotin (BV)-based regimens, and PD-1 blockade; however, drug cost and infrastructure barriers constrain translation to lower- and middle-income countries (LMICs). We conducted a narrative re...